1/3
MigVax is developing an oral COVID-19 sub-unit vaccine. 

The MigVax approach utilizes a chimeric protein that presents the viral proteins to the immune system via the oropharynx.

 

This method, based on the IBV vaccine, generates three kinds of immunological response:

  1. mucosal immunity- IgA

  2. Blood-based immunity-IgG

  3. Cell-mediated immunity.

The MigVax vaccine is based on a vaccine developed for Infectious Bronchitis Virus which is a coronavirus that infects chickens.​

MigVax and OurCrowd raises $12M for its COVID-19 vaccine efforts

Download a Mutual Press Release by MigVax and OurCrowd

MigVax team develop Covid-19 vaccine

Meet the Multidisciplinary MigVax Team

AdobeStock_319244858.jpeg

Read about the COVID-19 Pandemic

MIGAL grants its SPV MigVax exclusive worldwide license to use its vaccine technology
  • LinkedIn
  • Facebook
  • RSS

© 2020 by MigVax Ltd. All rights reserved.